Giving women at risk of premature birth a simple magnesium sulphate infusion can prevent their babies from developing cerebral palsy, a recent Cochrane review has confirmed.
To increase uptake of magnesium sulphate, the PReCePT programme was developed by Health Innovation West of England with University Hospitals Bristol and Weston. As a result of its regional impact, PReCePT was selected as national adoption and spread programme from 2018 to 2020 by the Health Innovation Network. PReCePT was the first ever perinatal quality improvement (QI) programme delivered at scale across the whole country, bringing together midwives, obstetricians and neonatologists.
Magnesium sulphate itself costs approximately £5 (~$6.50) per dose in England, and requires hospital admission with experienced staff to administer the drug safely to the mother. A new editorial for Cochrane by Karen Luyt, Clinical Lead for the PReCePT programme, calls for this intervention to be implemented more widely and equitably, as it is still not consistently available worldwide.
Karen Luyt, Professor in Neonatal Medicine at the University of Bristol, said: “Preterm birth is the leading cause of brain injury and cerebral palsy with lifelong impact on children and families. When the Cochrane meta-analysis was published in 2009, I realised that magnesium sulphate, given to mothers in preterm labour, was a potential game changer. The first effective neuroprotective treatment for preterm babies, preventing cerebral palsy by around 30%. We were early adopters at St Michael’s Hospital (University Hospitals Bristol and Weston NHS Foundation Trust).
“I discovered in 2014 that this potentially life-altering treatment was not widely used in England, despite high level evidence that it is effective at protecting preterm babies from brain injury and subsequent cerebral palsy. I was awarded Evidence to Practice Challenge support funding from our West of England Health Innovation Network and the PReCePT project was born. Our goal was to give every eligible mother in preterm labour the choice to receive magnesium sulphate and give every preterm baby the chance to develop to their full potential.
“The PReCePT collaboration managed to close the evidence-to-practice gap in England, achieve health equity for babies living in the most socio-economically deprived regions and build the evidence base for successful future implementation of perinatal interventions.”
Following correspondence with the Cochrane authors, Karen began implementing the findings in her own hospital through PReCePT. Supported by Health Innovation West of England and co-designed by parents and maternity ward staff, the programme provides practical tools and training to ensure eligible mothers are offered magnesium sulphate.
One of the first women to receive magnesium sulphate through the programme was Elly Salisbury. She was offered the drug when pregnant with her son Cormac, who is now a healthy 11-year old boy.
“It fills me with pride and joy that all mothers in my situation across England are offered magnesium sulphate thanks to the PReCePT programme,” says Elly. “Behind every infusion of magnesium sulphate is a little boy or girl, just like Cormac, and a family just like ours. Every family deserves the chance to be given this drug, wherever they are in the world. I hope that health systems around the world take inspiration from PReCePT’s success to make this a reality.”
Following the successful spread of the programme to all five trusts in the West of England, the Health Innovation Network rolled it out to all NHS maternity units in England. Between 2018 and 2023, magnesium sulphate was given to 14,270 eligible women across the country, resulting in an estimated 385 fewer cases of cerebral palsy.
The widespread use of this life-changing treatment was made possible by the original Cochrane review led by Professors Lex Doyle and Caroline Crowther.
“The first suggestions that magnesium sulphate might protect babies’ brains from cerebral palsy came from observational studies where it was being used for other purposes,” says Lex Doyle, Honorary Professor of Neonatal Paediatrics at the University of Melbourne. “Rates of cerebral palsy appeared to be lower in premature babies whose mothers had received the drug, but the evidence was inconclusive. Randomised clinical trials followed, and when we published our 2009 review which combined the results of five trials, the evidence showed a clear benefit in reducing rates of cerebral palsy in early childhood.
“It’s heartening to see the increased uptake of this intervention around the world, which is now being given to the majority of eligible mothers in many countries. However, due to the unpredictability of human childbirth, it’s impossible to reliably reach 100%. Some women in preterm labour deliver too quickly, with no opportunity for intervention, while others experience ‘false alarms’ and go on to give birth much later, even at term.”
Despite clear evidence that magnesium sulphate is both cost-effective and life-changing, not all mothers are receiving it. The Vermont Oxford Network collects data from over 1,400 participating neonatal units worldwide, primarily in the USA. Their data suggests that around two thirds of eligible women receive magnesium sulphate, and this figure is likely to be lower in low-resource settings that are underrepresented in the data.
Karen worked alongside clinicians around the world to develop materials to help people in lower-resource settings to implement magnesium sulphate alongside other interventions to help premature babies. In her new editorial in the Cochrane Library, she urges increased global uptake and implementation research in lower-resource settings.
“The trials combined in our review are all from high-income countries, where hospitals are comparatively well set-up to administer magnesium sulphate infusions and fulfil maternal and fetal monitoring requirements,” says Dr Emily Shepherd of the South Australian Health and Medical Research Institute, lead author of the updated Cochrane review. “In low resource settings, this may not always be possible. It would be helpful for future studies to establish the minimum effective dose, and alternative or simpler regimens, particularly intramuscular administration, to aid widespread implementation including across low and middle-income countries.
“We need further research to explore other questions to help optimise implementation. For example, is it better to deliver the drug as soon as women present to hospital in preterm labour, or as close to the birth as possible? Are the benefits the same regardless of how early the babies are born? We are currently undertaking a new research project to explore some of these questions based on existing data, which we hope will help to standardize international recommendations and aid translation. Our hope is that women whose children will likely not benefit are not exposed unnecessarily, and that all women whose children are likely to benefit are offered treatment across the globe.”
Find out out more about the impacts of the PReCePT programme.
For more information email healthinnowest.transformation@nhs.net.
Posted on September 24, 2024
News you may like
Cochrane review confirms magnesium sulphate can prevent cerebral palsy in premature babies
Giving women at risk of premature birth a simple magnesium sulphate infusion can prevent their babies from developing cerebral palsy, a recent Cochrane review has confirmed. To increase uptake of magnesium sulphate, the PReCePT programme was developed by Health Innovation West of England with University Hospitals Bristol and Weston. As a result of its regional…
Read more
Black Maternity Matters statement: CQC national review of maternity services in England 2022 to 2024
The Black Maternity Matters collaborative welcomes the Care Quality Commission (CQC) report on its national review of maternity services in England, 2022 to 2024. One of the report findings is that the CQC remains concerned about “the inherent inequalities in access to maternity services, experience and outcomes for women, and the safety risks this presents.” The…
Read more
Putting evidence into practice – supporting people at high risk of developing hypertension in pregnancy
Following our Evidence into Practice call earlier this year, we are delighted to announce the successful evidence-based innovation that will now receive our support for rollout across the wider West of England. From the 20 high-quality applications received, we have selected the outpatient hypertension pathway for women and birthing people at high risk of developing…
Read more
